Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2016 Filed Dec 5, 2016 11:24 UTC |
Hanson Bryan CEVP, President, MITG
|
Tax withholdingOrdinary Shares | 4,155 | $71.88 | $298,661.40 |
DisclosureSEC source: 0001127602-16-069052 · form4.xml · nonDerivative · entry 1 Hanson Bryan C · CIK 0001524349 · EVP, President, MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,586 F1 · security: This balance increased by 549 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 12:32 UTC |
Lenehan James TDirector
|
PurchaseOrdinary Shares | 2,000 | $73.27 | $146,532.60 |
DisclosureSEC source: 0001127602-16-068289 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,252 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $73.245 to $73.27, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2 · balance_after: This balance increased by 119 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 28, 2016 Filed Oct 31, 2016 15:20 UTC |
Surface Carol ASVP, Chief HR Officer
|
Tax withholdingOrdinary Shares | 12,618 | $81.93 | $1,033,792.74 |
DisclosureSEC source: 0001127602-16-065541 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,346 F1 · balance_after: This balance increased by 558 shares due to exempt transactions such as ESPP and dividend reinvestment. Read SEC document |
| September 27, 2016 Filed Sep 28, 2016 20:25 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
SaleOrdinary Shares | 17,141 | $86.70 | $1,486,056.14 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 3 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,085 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.675 to $86.725, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 30,624 | $0.00 Strike: $35.92 | $0.00 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,624 shares Expires 2019-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 30,624 New Medtronic ordinary shares for $35.92 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 30,624 Medtronic common stock shares for $35.92 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
SaleOrdinary Shares | 25,199 | $86.67 | $2,183,997.33 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,226 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $86.57 to $86.735, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC |
Kuntz RichardSrVP & Chief Scien, Clin, Reg
|
Exercise / conversionOrdinary Shares | 30,624 | $35.92 | $1,100,014.08 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,813 | $0.00 Strike: $44.13 | $0.00 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · derivative · entry 12 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,813 shares Expires 2020-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option to purchase 1,813 New Medtronic ordinary shares for $44.13 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,813 Medtronic common stock shares for $44.13 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,671 | $0.00 Strike: $29.96 | $0.00 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · derivative · entry 11 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,671 shares Expires 2019-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option to purchase 2,671 New Medtronic ordinary shares for $29.96 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 2,671 Medtronic common stock shares for $29.96 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,590 | $0.00 Strike: $50.34 | $0.00 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · derivative · entry 10 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,590 shares Expires 2018-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase 1,590 New Medtronic ordinary shares for $50.34 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,590 Medtronic common stock shares for $50.34 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,010 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · derivative · entry 9 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,010 shares Expires 2017-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase 1,010 New Medtronic ordinary shares for $52.84 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,010 Medtronic common stock shares for $52.84 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,977 | $0.00 Strike: $51.61 | $0.00 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · derivative · entry 8 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,977 shares Expires 2017-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 2,713 New Medtronic ordinary shares for $51.61 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 2,713 Medtronic common stock shares for $51.61 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. F4 · derivative.exercise_date: This option to purchase 264 New Medtronic ordinary shares for $51.61 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 264 Medtronic common stock shares for $51.61 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
SaleOrdinary Shares | 7,907 | $85.45 | $675,613.62 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 6 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,375 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.433 to $85.453, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionOrdinary Shares | 1,813 | $44.13 | $80,007.69 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 5 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionOrdinary Shares | 2,671 | $29.96 | $80,023.16 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 4 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionOrdinary Shares | 1,590 | $50.34 | $80,040.60 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 3 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionOrdinary Shares | 1,010 | $52.84 | $53,368.40 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 2 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:06 UTC |
Powell Kendall JDirector
|
Exercise / conversionOrdinary Shares | 2,977 | $51.61 | $153,642.97 |
DisclosureSEC source: 0001127602-16-062825 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 110 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 20:45 UTC |
ISHRAK OMARDirector · Chairman & CEO
|
SaleOrdinary Shares | 61,925 | $84.93 | $5,259,414.10 |
DisclosureSEC source: 0001127602-16-062808 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,916 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.40 to $85.30, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.